Amarin Corp Plcuk 8-K, filed Aug 19, 2022
Amarin Corp Plcuk (AMRN)
About this 8-K
Amarin Corp Plcuk filed this 8-K on August 19, 2022.
Items reported
- Item 7.01: Regulation FD disclosure
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| Not applicable | ||
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: +
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 7.01 | Regulation FD Disclosure. |
On August 19, 2022, Amarin Deutschland GmbH, a wholly-owned subsidiary of Amarin Corporation plc (“Amarin”), issued a press release in Germany titled “Amarin Provides Update on VAZKEPA® (icosapent ethyl) Pricing Negotiations in Germany.” An English translation of the press release is furnished herewith as Exhibit 99.1.
The information in this Item 7.01 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
| Item 8.01 | Other Events. |
In light of the developments in Germany whereby a viable agreement on the reimbursement price of Vazkepa® (icosapent ethyl) could not be reached, Amarin will cease commercial activities in Germany, effective September 1, 2022. Amarin estimates that it will incur a charge of approximately $4 million (USD), related to the outcome of German price negotiations, all of which are cash expenditures related to termination benefits and associated costs. Amarin expects to record this charge in the third quarter of 2022.
Forward-looking statement
This Current Report on Form 8-K and the press release furnished herewith contain forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements contained herein and therein which do not describe historical facts, including, among others, beliefs about the medical benefits of Vazkepa and Amarin’s efforts to secure acceptable reimbursement, the estimate of the restructuring charge and the expected timing of such charge, and our desire to re-submit a pricing and reimbursement dossier and advance in other key European markets, are forward-looking statements. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. In particular, the restructuring charge associated with the cessation of commercial activities in Germany may be higher than expected and Amarin’s ability to maintain and grow revenue from sales of Vazkepa in Europe may be materially adversely affected.
Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with administrative decisions and the bases for such decisions. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin’s filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. |
Description | |
| 99.1 | Press Release, dated August 19, 2022 (furnished herewith) | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 19, 2022 | Amarin Corporation plc | |||||
| By: | /s/ Karim Mikhail | |||||
| Karim Mikhail | ||||||
| President and Chief Executive Officer | ||||||
Exhibit 99.1
Amarin Provides Update on VAZKEPA® (icosapent ethyl) Pricing Negotiations in Germany
Frankfurt am Main, August 19, 2022 – Amarin Deutschland GmbH today announced that after the conclusion of the fourth and final round of negotiations with the National Association of Statutory Health Insurance Funds (Spitzenverband der gesetzlichen Krankenversicherungen – GKV-SV), a viable agreement on the reimbursement price of Vazkepa® (icosapent ethyl) in Germany could not be reached, despite Amarin’s best efforts to find a solution in the interest of cardiovascular patients across the country. As previously indicated by the company, the matter is now moving to the Arbitration Board for a final decision.
As a result of the negotiation outcome with the GKV-SV, Amarin Deutschland GmbH has been forced to suspend the supply of its only product, Vazkepa in Germany, and discontinue its German business operations. This unavoidable measure will be implemented as of September 1st, 2022.
Amarin Deutschland GmbH is disappointed by this outcome as it strongly believes that Vazkepa offers significant medical benefits to adult high-risk patients with cardiovascular disease and triglyceride levels of ≥ 150 mg/dL (1.7 mmol/L) throughout Germany1, as demonstrated by the results of the REDUCE-IT study2. These results were also recognized by the European Medicines Agency (EMA) and led to a positive benefit assessment in several European countries such as France, the Netherlands, Sweden and the UK. Vazkepa has received final positive reimbursement decision and pricing in Sweden and the UK.
In the ranking of cause-of-death statistics, for decades, cardiovascular diseases (CVDs) are the leading cause of death in Germany. In 2020, 985.572 people died in Germany from any cause, wherein CVDs were responsible for 34.3% of these deaths; 18.3 % occurred among women and 16.0 % among men (Destatis 2020)3. Apart from mortality, CVD related morbidity causes an important burden of quality of life lost in Germany.
“We deeply regret having to take this drastic decision at a critical time where high-risk cardiovascular patients in Germany are essentially being denied a medically effective therapeutic option that other European health authorities have recognized as being valuable in the fight against cardiovascular disease,” said Laurent Abuaf, Senior Vice President and President Europe of Amarin Corporation.
| 1 | Vazkepa® (icosapent ethyl): Summary of Product Characteristics. Available from: |
| https://www.ema.europa.eu/en/documents/product-information/vazkepa-epar-product-information_en.pdf [accessed August 2022] |
| 2 | Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. |
| 3 |
https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Gesundheit/Todesursachen/Tabellen/gestorbene_anzahl.html |
“For Amarin, which commercializes one single product, it is simply not economically viable to keep Vazkepa on the market in Germany given the outcomes of the G-BA assessment earlier this year, and the subsequent GKV-SV pricing negotiations,” said Abuaf.
Following local German legislation which allows re-submission of a pricing and reimbursement dossier with new data, Amarin plans to resubmit once we have a new dossier ready.
Today’s announcement in Germany has no impact on Amarin’s commercial activities in other European countries, nor on its ongoing market access discussions throughout Europe. The Company remains confident and resolute in its commitment to bringing Vazkepa to as many eligible patients across the continent as possible. The Company continues to focus on building on the important progress it has made in other key markets across Europe, and we look forward to advancing these opportunities in the weeks and months to come.
For physicians in Germany who are interested in continuing the treatment of their patients with Vazkepa®, a step-by-step guide is available at https://www.deutschesapothekenportal.de/download/public/arbeitshilfen/dap_arbeitshilfe _54.pdf
In addition, Amarin Deutschland GmbH recommends that treating physicians contact an international pharmacy in their vicinity to discuss options to secure treatment for their patients.
***